Siponimod: a new view at the therapy of secondary progressive multiple sclerosis

Kolontareva Yu.M.; Krasnov V.S.

doi:https://doi.org/10.17116/jnevro2021121071124

Xlstat 2023 Crack [verified] Jun 2026

The statistical community relies on trust and reproducibility. Using unverified, modified software violates both.

If the cost of a full license is a barrier, there are several legal avenues to explore:

Addinsoft offers a lower-tier "Base" version starting at $195 per year. For many users, this includes all essential statistical functions (descriptive stats, t-tests, ANOVA, correlation, regression). You can upgrade later if needed.

XLSTAT is a statistical software that provides a comprehensive set of tools for data analysis, visualization, and modeling. The software offers a wide range of features, including:

Visit addinsoft.com, click "Download free trial," install, and activate with your email address.

Krasnov V.S.

Pavlov First St. Petersburg State Medical University

Kolontareva Yu.M.

Novartis Pharma LLC

Siponimod: a new view at the therapy of secondary progressive multiple sclerosis

Authors:

Krasnov V.S., Kolontareva Yu.M.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(7): 124‑129

DOI: 10.17116/jnevro2021121071124

Read: 10020 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Krasnov VS, Kolontareva YuM. Siponimod: a new view at the therapy of secondary progressive multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(7):124‑129. (In Russ.)
https://doi.org/10.17116/jnevro2021121071124

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

A comprehensive study of Alzheimer’s disease biomarkers in plasma and cerebrospinal fluid. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):43-53

Study of neurodegeneration in multiple sclerosis using optical coherence tomography of the retina and magnetic resonance morphometry of the brain. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):66-72

Neurogenesis in neurodegeneration: multifactorial regulation, mechanisms of impairment, and therapeutic strategies. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(12):14-21

Pathophysiological and neurobiological basis for the development of depression in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(1):7-12

Amyloidogenesis and neurotrophic dysfunction in age-related macular degeneration in correlation with Alzheimer’s disease. Russian Journal of Archive of Pathology. 2025;(6):61-68

Age-related pathomorphological changes in the brain of non-human primates. Molecular Genetics, Microbiology and Virology. 2025;(4-2):143-149

Abstract:

Siponimod is a selective modulator of sphingosine-1-phosphate (S1P) receptors of types 1 and 5, registered in the Russian Federation for the treatment of patients with secondary progressive multiple sclerosis (SPMS), regardless of the presence or absence of exacerbations. The effectiveness of the drug in comparison with placebo was demonstrated in patients with SPMS in the international clinical trial EXPAND (phase III). This review devotes actual problems in the treatment of patients with SPMS, discusses the pathophysiology of multiple sclerosis progression, describes the peripheral and central mechanisms of siponimod action and its differences from fingolimod. According to analysis of scientific literature experimental, clinical and neuroimaging data are presented, which could explain the reasons for the successful use of siponimod in patients with SPMS, taking into account the pathophysiological mechanisms of the development of progression and the mechanisms of drug action.

Keywords:

secondary progressive multiple sclerosis

siponimod

neurodegeneration

remyelination